Revista Espanola de Cardiologia Suplementos最新文献

筛选
英文 中文
Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones clínicas 肾素-血管紧张素-醛固酮系统与covid - 19。临床意义
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30032-7
Pedro Caravaca Pérez , Laura Morán Fernández , María Dolores García-Cosio , Juan F. Delgado
{"title":"Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones clínicas","authors":"Pedro Caravaca Pérez ,&nbsp;Laura Morán Fernández ,&nbsp;María Dolores García-Cosio ,&nbsp;Juan F. Delgado","doi":"10.1016/S1131-3587(20)30032-7","DOIUrl":"10.1016/S1131-3587(20)30032-7","url":null,"abstract":"<div><p>The pandemic caused by the rapid spread of the SARS-CoV-2 virus has produced the greatest health crisis of modern times. The close relationship between the virus and angiotensin-II converting enzyme has provoked a torrent of speculation about the possible role of the renin-angiotensin-aldosterone system (RAAS) in mediating infection. The subsequent alarm has raised questions about the use of RAAS inhibitors, such as angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers. The result has been the publication of several studies that have failed to find an association between the use of RAAS inhibitors and greater susceptibility to infección or a worse clínical outlook. This review considers the most significant aspects of the interaction between SARS-CoV-2 and the RAAS and the clínical implications of using RAAS inhibitors during the pandemic.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Papel de los lípidos en la ateroesclerosis 脂质在动脉粥样硬化中的作用
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30023-6
Fernando Civeira , Victoria Marco-Benedí , Ana Cenarro
{"title":"Papel de los lípidos en la ateroesclerosis","authors":"Fernando Civeira ,&nbsp;Victoria Marco-Benedí ,&nbsp;Ana Cenarro","doi":"10.1016/S1131-3587(20)30023-6","DOIUrl":"10.1016/S1131-3587(20)30023-6","url":null,"abstract":"<div><p>In recent years, it has been shown that the circulating level of particles containing apolipoprotein B, especially low-density lipoproteins (LDLs) and lipoprotein(a), is not a risk factor for cardiovascular disease but is instead a major etiological factor. Indisputable evidence has come from prospective observational studies, Mendelian randomization studies, animal models of arteriosclerosis involving the manipulation of lipid-related genes, human genetic diseases (e.g. monogenic familial hypercholesterolemia and hypercholesterolemia associated with an elevated lipoprotein(a) concentration), and interventional studies with lipid-lowering agents. This article reviews these findings and summarizes current understanding of the principle pathogenic mechanisms that make LDL cholesterol one of the main causes of atherosclerotic cardiovascular disease.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hitos históricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteina convertasa subtilisina/kexina tipo 9 枯草赖氨酸/克辛9型原蛋白转换酶抑制剂时代之前降脂治疗的历史里程碑
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30024-8
Pedro-Botet Juan, Elisenda Climent, David Benaiges
{"title":"Hitos históricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteina convertasa subtilisina/kexina tipo 9","authors":"Pedro-Botet Juan,&nbsp;Elisenda Climent,&nbsp;David Benaiges","doi":"10.1016/S1131-3587(20)30024-8","DOIUrl":"10.1016/S1131-3587(20)30024-8","url":null,"abstract":"<div><p>There is extensive, strong evidence that low-density lipoprotein (LDL) cholesterol is a causal factor for atherosclerosis. The use of lipid-lowering drugs to reduce the atherogenic load of lipoproteins containing apolipoprotein B, mainly LDLs, slows the progression of atheromatous disease and could even reverse it if treatment is started early and aggressively. This review provides a historical perspective on the development of the various lipid-lowering drugs used for cardiovascular prevention, excluding proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors, and summarizes the findings of the main prospective interventional clinical trials of individual agents in order to identify the potential cardiovascular benefits associated with their ability to reduce LDL-cholesterol concentrations.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Coordinación de unidades de rehabilitación cardiaca y de insuficiencia cardiaca. Continuidad asistencial en la insuficiencia cardiaca 协调心脏康复和心力衰竭单位。心力衰竭的持续护理
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30017-0
José Manuel García Pinilla , Vicente Arrarte
{"title":"Coordinación de unidades de rehabilitación cardiaca y de insuficiencia cardiaca. Continuidad asistencial en la insuficiencia cardiaca","authors":"José Manuel García Pinilla ,&nbsp;Vicente Arrarte","doi":"10.1016/S1131-3587(20)30017-0","DOIUrl":"10.1016/S1131-3587(20)30017-0","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30017-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83935235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Fisiopatología de la enfermedad cardiovascular en pacientes con COVID-19. Isquemia, trombosis y disfunción cardiaca COVID-19患者心血管疾病的病理生理学。缺血、血栓形成和心脏功能障碍
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30028-5
José Rozado , Ana Ayesta , César Morís , Pablo Avanzas
{"title":"Fisiopatología de la enfermedad cardiovascular en pacientes con COVID-19. Isquemia, trombosis y disfunción cardiaca","authors":"José Rozado ,&nbsp;Ana Ayesta ,&nbsp;César Morís ,&nbsp;Pablo Avanzas","doi":"10.1016/S1131-3587(20)30028-5","DOIUrl":"10.1016/S1131-3587(20)30028-5","url":null,"abstract":"<div><p>Cardiovascular complications are highly prevalent in patients with COVID-19 and frequently lead to hospitalization, death and long-term morbidity. This article describes the principle pathophysiological mechanisms involved in the development of these complications. After the initial viremia, viralinvasión and replication occurs in the lungs, accompanied by immune system activation, cytokine release and the induction of a proinflammatory state, with sepsis and multiorgan failure. Myocardial injury could be due to the direct effect of viralinvasión and a local inflammatory response or to the indirect effect of inappropriate systemic inflammation involving a cytokine storm. Furthermore, the development of a prothrombotic state, together with vascular disease due to the virus, could trigger ischemic and thrombotic events secondary to microvascular damage or to the destabilization of pre-existing atheromatous plaque. New research is needed to reveal the pathophysiological mechanisms underlying these cardiovascular events and to support the development of effective new treatments.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30028-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Aplicabilidad de los consensos de expertos de unidades de insuficiencia cardiaca/rehabilitación cardiaca y RehaCtivAP con respecto a la COVID-19 心力衰竭/心脏康复和康复部门专家共识对新冠肺炎的适用性
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30021-2
Vicente Arrarte , Raquel Campuzano
{"title":"Aplicabilidad de los consensos de expertos de unidades de insuficiencia cardiaca/rehabilitación cardiaca y RehaCtivAP con respecto a la COVID-19","authors":"Vicente Arrarte ,&nbsp;Raquel Campuzano","doi":"10.1016/S1131-3587(20)30021-2","DOIUrl":"10.1016/S1131-3587(20)30021-2","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30021-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48087527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Anticoagulación del paciente anciano pluripatológico con fibrilación auricular no valvular: papel del rivaroxabán 老年多病理性非瓣膜房颤患者的抗凝作用:利伐沙班的作用
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30011-X
Antoni Riera-Mestre , Miguel Camafort , Jose María Suriñach , Francisco José Muñoz Rodríguez , Ferran Padilla , Jaume Francisco-Pascual , José Mateo Arranz , Antonio Martínez Rubio , Roger Villuendas Sabaté , Román Freixa-Pamias , Carmen Suárez Fernández , Amparo Santamaría
{"title":"Anticoagulación del paciente anciano pluripatológico con fibrilación auricular no valvular: papel del rivaroxabán","authors":"Antoni Riera-Mestre ,&nbsp;Miguel Camafort ,&nbsp;Jose María Suriñach ,&nbsp;Francisco José Muñoz Rodríguez ,&nbsp;Ferran Padilla ,&nbsp;Jaume Francisco-Pascual ,&nbsp;José Mateo Arranz ,&nbsp;Antonio Martínez Rubio ,&nbsp;Roger Villuendas Sabaté ,&nbsp;Román Freixa-Pamias ,&nbsp;Carmen Suárez Fernández ,&nbsp;Amparo Santamaría","doi":"10.1016/S1131-3587(20)30011-X","DOIUrl":"10.1016/S1131-3587(20)30011-X","url":null,"abstract":"<div><p>Atrial fibrillation is common in elderly patients. Although vitamin K antagonists have been widely used for many years, they have a number of limitations in elderly patients, who are particularly susceptible to bleeding and in whom anticoagulation control is poorer than in the general population. Direct oral anticoagulants have been shown to be a better therapeutic option for these patients, not only because they are simpler to use, but also because they are more effective and safer than vitamin K antagonists. Moreover, their performance in practice is generally consistent with that in pivotal clinical trials. Nevertheless, there is a tendency to administer inappropriate doses to elderly patients, generally underdosing, particularly in certain subgroups. This can result in less protection against stroke without any clear reduction in bleeding risk. Rivaroxaban has been widely studied in the elderly population, not only in clinical trials, but also in a range of studies in routine clinical practice – findings have been highly consistent. According to these studies, and compared to vitamin K antagonists, rivaroxaban reduces the risk of stroke without increasing the rate of fatal bleeding, with a net clinical benefit in patients with nonvalvular atrial fibrillation and a high thromboembolic risk.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30011-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán 高危心血管和心房颤动患者:利伐沙班的作用
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30014-5
Vivencio Barrios , David Vivas , Felipe Atienza Fernández , Miguel Ángel Arias , Raquel Diaz Simón , Aquilino Sánchez Purificación , Gonzalo Barón-Esquivias
{"title":"Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán","authors":"Vivencio Barrios ,&nbsp;David Vivas ,&nbsp;Felipe Atienza Fernández ,&nbsp;Miguel Ángel Arias ,&nbsp;Raquel Diaz Simón ,&nbsp;Aquilino Sánchez Purificación ,&nbsp;Gonzalo Barón-Esquivias","doi":"10.1016/S1131-3587(20)30014-5","DOIUrl":"10.1016/S1131-3587(20)30014-5","url":null,"abstract":"<div><p>Traditionally the primary aim of anticoagulation in patients with atrial fibrillation was the prevention of stroke. However, these patients actually have numerous comorbidities that also have a substantial impact on prognosis and that must be treated. These considerations should also play a role in selecting the best anticoagulant treatment for patients with a high cardiovascular risk. In general, direct oral anticoagulants have consistently been shown to have superior efficacy and safety to warfarin, irrespective of whether patients have a history of stroke, transient ischemic attack, diabetes, renal insufficiency or myocardial infarction. In particular, studies have shown that rivaroxaban is associated with a lower risk of myocardial infarction and fewer renal complications than warfarin. In a subgroup study of the ROCKET-AF trial, it was found that rivaroxaban significantly reduced cardiovascular mortality in patients with diabetes mellitus (by 20%). Moreover, studies carried out in routine clinical practice showed that the drug significantly reduces the risk of both major cardiovascular events and peripheral artery disease. As a result, rivaroxaban could be considered the preferred option for anticoagulation in patients with nonvalvular atrial fibrillation and a high cardiovascular risk, given the additional benefits it provides in this population.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30014-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56635767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novedades en la guía de práctica clínica de la Sociedad Europea de Cardiología en dislipemias: el peso de la evidencia 欧洲心脏病学会血脂异常临床实践指南的更新:证据的权重
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30026-1
Carlos Escobar , Vivencio Barrios
{"title":"Novedades en la guía de práctica clínica de la Sociedad Europea de Cardiología en dislipemias: el peso de la evidencia","authors":"Carlos Escobar ,&nbsp;Vivencio Barrios","doi":"10.1016/S1131-3587(20)30026-1","DOIUrl":"10.1016/S1131-3587(20)30026-1","url":null,"abstract":"<div><p>The publication of pivotal clínical trials, such as the FOURIER and ODYSSEY OUTCOMES trials, and of other types of clínical study since 2016 has resulted in changes in the clínical practice guidelines for patients with dyslipidemias, which were updated in 2019. Cardiovascular risk stratification has been improved by the use of: (i) noninvasive cardiovascular imaging, involving for example the coronary calcium score, carotid or femoral artery ultrasonography, and coronary CT angiography; and (ii) biomarkers, particularly lipoprotein(a). However, the principle novelties were much stricter low-density lipoprotein cholesterol treatment targets and new recommendations on ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, added to statins, which have now become class-I treatment recommendations. Furthermore, the Spanish Society of Cardiology’s consensus on improving lipid control in secondary prevención provides a simple and practical way of optimizing lipid-lowering therapy.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56636302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19. Las consecuencias sociales, sanitarias y cardiovasculares 新型冠状病毒肺炎社会、健康和心血管后果
Revista Espanola de Cardiologia Suplementos Pub Date : 2020-01-01 DOI: 10.1016/S1131-3587(20)30027-3
Ángel Cequier Fillat , José Ramón González-Juanatey
{"title":"COVID-19. Las consecuencias sociales, sanitarias y cardiovasculares","authors":"Ángel Cequier Fillat ,&nbsp;José Ramón González-Juanatey","doi":"10.1016/S1131-3587(20)30027-3","DOIUrl":"10.1016/S1131-3587(20)30027-3","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(20)30027-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47222638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信